Menu
Your Cart

Apostle MiniGenomics Viral Total NA Isolation Kit (6144 preps)

Apostle MiniGenomics Viral Total NA Isolation Kit (6144 preps)
Secured Shopping
Best security features
Apostle MiniGenomics Viral Total NA Isolation Kit (6144 preps)
  • For fast extraction and purification of viral nucleic acids from various kinds of biological samples collected in multiple transport media.  
  • Novel and original magnetic nanoparticle technology for nucleic acids isolation.  
  • Various sample types: swabs, saliva, blood.  
  • Optimized standardized protocol for viral total NA isolation in 30 min without heating.  
  • Compatible with multiple high-throughput automated nucleic acid extraction platforms.  
  • Please note this product is not returnable.
  • Configuration: 200uL X 6144 preps (A200619-6144).  
  • Cat #: A200619-6144.

Documentation:

Product brochure: Apostle-COVID-19-Viral-RNA-Isolation-System.pdf

System protocol: Apostle-MiniGenomics-Viral-Total-NA-Isolation-MagTouch-protocol.pdf

Application Note: Application-Note-Apostle-Viral-RNA-Isolation-System.pdf

This links directs to an Application Note on the Apostle COVID-19 Viral RNA Extraction System, applied in the effective detection of SARS-CoV-2 in over 15 million clinical samples by our clients. 

Material Safety Data Sheet (MSDS): Apostle_MiniGenomics_Viral_Total_NA_Isolation_Fast_Kit_Material_Safety_01.pdf


Inclusion in US FDA IVD EUA - Molecular Diagnostic Tests for SARS-CoV-2

Apostle RNA extraction method is included in a US FDA EUA authorized SARS-CoV-2 molecular diagnostic test: Fulgent COVID-19 by RT-PCT Test.


More information

$14,500.00
Tags: COVID-19
A new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. Congratulations to this clinical research team. To date, the Apostle MiniMax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.